Imperative Care has reported results from a post-hoc analysis of the SYMPHONY-PE trial, evaluating the impact of early mechanical thrombectomy in patients with intermediate-risk pulmonary embolism (PE).
The analysis compared patients treated with the Symphony thrombectomy system within 12 hours of diagnosis versus those treated later. Results suggested that earlier intervention may lead to greater short-term improvements in right ventricular function and pulmonary artery pressure.
Related: VahatiCor enrolls first U.S. patient in SERRA-I clinical study of A-FLUX Reducer System
Among 109 patients, 48 received early treatment. The early-treatment group showed a larger reduction in pulmonary artery pressure and greater improvement in the RV/LV ratio, indicating improved heart recovery measures.
Safety outcomes were similar between groups, with no device-related serious adverse events or deaths reported.
Imperative Care CEO Fred Khosravi said:
“We are encouraged by the growing physician confidence in Symphony and the continued clinical evidence supporting its procedural efficiency and favourable safety profile.”
The findings add to clinical evidence supporting the Symphony system, which received FDA clearance in 2025, as Imperative Care continues expanding its pulmonary embolism treatment platform.
